Ultime notizie per  (OTC:HEPZF) Azioni

WIIM

PSTX

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

Scotiabank analyst Mario Saric maintains Killam Apartment REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KMP#TSX">KMP</a>) with a Sector Perform and raises the price target from C$20.5 to C$21.

News

Price Target

Analyst Ratings

TSX:KMP

TSX:KMP/UN

Scotiabank Maintains Sector Perform on Killam Apartment REIT, Raises Price Target to C$21

Truist Securities analyst Neal Dingmann maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Buy and lowers the price target from $36 to $33.

Truist Securities Maintains Buy on APA, Lowers Price Target to $33

Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) co-founder Sergey Nazarov on Friday said &#8220;the party&#8217;s back on&#8221; for cryptocurrency markets, predicting substantial industry growth amid potential changes in the U.S. regulatory <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">landscape under Donald Trump&#8216;s presidency</a>.
What Happened: &#8220;This is just the beginning basically. This is like the party&#8217;s back on and there&#8217;s going to be huge huge growth in all categories of crypto,&#8221; Nazarov <a href="https://x.com/ChainLinkGod/status/1854553832396828796">told</a> CNBC, expressing optimism about the industry&#8217;s trajectory.
Nazarov emphasized that cryptocurrency&#8217;s fundamental benefits to society outweigh regulatory concerns. 
&#8220;I think that crypto fundamentally benefits society and makes things work in a much more reliable way than they do now,&#8221; he stated, citing <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41654131/pro-crypto-congress-in-2025-experts-see-stablecoins-as-key-area-for-advancement">stablecoins</a> and tokenized funds as examples of successful implementation.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41841793/bitcoin-ethereum-solana-rally-does-not-mean-all-cryptocurrencies-will-moon-10x-research">Bitcoin, Ethereum, Solana Rally Does Not Mean All Cryptocurrencies Will Moon: 10x Research</a>
Drawing parallels with Asian crypto hubs, Nazarov pointed to successful regulatory frameworks in <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40901724/singapores-dbs-bank-launches-bitcoin-and-ethereum-options-trading-for-institutional-client">Singapore</a> and Hong Kong.
&#8220;More regulation doesn&#8217;t mean better markets, it just means kind of muted markets with less innovation,&#8221; he explained, advocating for a more permissive approach to <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41823388/the-trump-effect-a-deep-dive-into-how-the-crypto-landscape-will-change-in-2025-and-beyond">cryptocurrency regulation</a>.
Price Action: Chainlink has followed other cryptocurrencies&#8217; uptrend since the start of October.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Price</td>
<td>1-day performance</td>
<td>7-day performance</td>
<td>30-day performance</td>
</tr>
<tr>
<td>$13.32</td>
<td>+8.6%</td>
<td>+14.7%</td>
<td>+25.6%</td>
</tr>
</tbody>
</table>
</figure>
The Chainlink co-founder&#8217;s perspectives align with growing institutional interest in digital assets, a topic that will be further explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814454/donald-trump-could-pardon-ross-ulbricht-january-6-protestors-and-one-other-controversial-f">Donald Trump Could Pardon Ross Ulbricht, January 6 Protestors And One Other Controversial Figure, Polymarket Traders Speculate</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$LINK

'The Party's Back On'—Chainlink Co-Founder Predicts Major Crypto Growth Under Trump Presidency

EXFY

Expensify shares are trading higher after the company reported better-than-expected Q3 financial results.

Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) reported a third-quarter 2024 adjusted EPS of 80 cents, beating the management guidance of 77 cents to 79 cents and the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">Wall Street estimate of 78 cents</a>.
This was driven by top-line strength in Medical Products &amp; Therapies and Kidney Care, continued improvements in the integrated supply chain, and disciplined operating expense management.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41403928/us-hospitals-face-critical-iv-fluid-shortage-after-baxter-facility-shuts-down-due-to-hurricane-hel" rel="noreferrer noopener">US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene</a>
The Deerfield, Illinois-based company reported sales of $3.85 billion, in line with consensus.
Baxter&#8217;s worldwide sales include continuing sales of $2.69 billion and discontinued operations (kidney care) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41840934/baxter-reports-third-quarter-2024-results" rel="noreferrer noopener">sales of $1.15 billion</a>.
Excluding Q3 2023 BioPharma Solutions (BPS) sales and including sales of Kidney Care in both periods, worldwide Baxter sales grew 4% on both a reported and constant currency basis, in line with the company&#8217;s prior guidance.
Adjusted EPS from continuing operations was 49 cents, up 14% year-over-year.
Revenue from Medical Products &amp; Therapies increased 7% to $1.34 billion, Healthcare Systems &amp; Technologies sales increased 1% to $752 million, and Pharmaceuticals sales were up 1% to $588 million.
Last week, Baxter said it has restarted North Cove&#8217;s highest-throughput IV solutions manufacturing line.
At its peak operation (before Hurricane Helene), this line represented approximately 25% of the site&#8217;s total production and approximately 50% of the site&#8217;s production of one-liter IV solutions, the most commonly used size by hospitals and clinics.
Baxter&#8217;s current expectation is that new product from North Cove could begin shipping to distributors and customers by the end of November, ahead of its original expectations.
Guidance: &#8220;While the hurricane&#8217;s aftermath is expected to have an impact on our near-term financial outlook, we remain confident in Baxter&#8217;s outlook and growth trajectory following completion of the pending Kidney Care sale,&#8221; said José (Joe) Almeida, chair, president &amp; CEO.
Baxter expects fourth-quarter adjusted EPS of 77 cents to 81 cents, with 50 cents to 53 cents expected from continuing operations.
For the fourth quarter, the company forecasts sales from continuing operations to decline in low-single digits on a reported and constant currency basis.
For fiscal year 2024, Baxter sees adjusted EPS of $2.90-$2.94 compared to a consensus of $2.95 and <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40191263/baxter-lifts-annual-outlook-after-strong-q2-beat-medical-devices-sales" rel="noreferrer noopener">prior guidance of $2.93-$3.01</a>, including $1.81-$1.84 from continuing operations.
The company <a target="_blank" href="https://s22.q4cdn.com/911189824/files/doc_financials/2024/q3/Baxter_Reports_Third-Quarter_2024_Results_Presentation.pdf" rel="noreferrer noopener">expects</a> sales (from continuing operations) growth of around 2%.
Baxter anticipates a full-year 2025 adjusted operating margin of approximately 16.5% on a continuing operations basis, which reflects an anticipated 100 basis point negative impact due to stranded costs. The company expects to offset these stranded costs in 2027.
Price Action: BAX stock is down 1.22% at $35.60 during the premarket session at last check Friday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41843534/astrazeneca-amgens-asthma-drug-aces-late-stage-study-in-patients-with-chronic-rhinosinusitis" target="_blank" rel="noreferrer noopener">AstraZeneca/Amgen&#8217;s Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis</a></li>
</ul>
Image: Shutterstock

Earnings

Guidance

Health Care

General

Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook

Truist Securities analyst Tobey Sommer maintains AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) with a Buy and lowers the price target from $50 to $47.

Truist Securities Maintains Buy on AMN Healthcare Services, Lowers Price Target to $47

Benchmark analyst Mike Hickey reiterates PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) with a Hold.

Reiteration

PENN

Benchmark Reiterates Hold on PENN Entertainment

LTRX

Lantronix shares are trading lower after the company reported worse-than-expected Q1 financial results and issued Q2 guidance below estimates. Also, the company announced the acquisition of DXS's NetComm enterprise IoT portfolio.

Scotiabank analyst Nick Altmann maintains JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) with a Sector Perform and raises the price target from $25 to $30.

FROG

Scotiabank Maintains Sector Perform on JFrog, Raises Price Target to $30

UEIC

Universal Electronics shares are trading higher after the company issued Q4 revenue guidance above estimates. Also, Rosenblatt upgraded the stock from Neutral to Buy.

Piper Sandler analyst Brent Bracelin maintains OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Overweight and raises the price target from $34 to $37.

Piper Sandler Maintains Overweight on OneStream, Raises Price Target to $37

Scotiabank analyst Phil Hardie maintains IGM Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IGM#TSX">IGM</a>) with a Sector Perform and raises the price target from C$53 to C$56.

TSX:IGM

Scotiabank Maintains Sector Perform on IGM Financial, Raises Price Target to C$56

APYX

Apyx Medical shares are trading lower after the company cut its FY24 and FY25 revenue guidance.

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>, Euronext Amsterdam: VEON))), a global digital operator, is pleased to announce that a VEON delegation led by VEON Chairman and Founder Augie Fabela, VEON Group CEO Kaan Terzioglu and Jazz CEO Aamir Ibrahim visited Prime Minister of Pakistan Shehbaz Sharif today in Islamabad, to discuss the advancement of the country's digital landscape.
The Prime Minister commended Jazz's role in driving digital transformation and fostering economic empowerment through technology. During the meeting, the VEON delegation provided a comprehensive overview of VEON's substantial investments in Pakistan's digital infrastructure through Jazz and Mobilink Bank, serving more than 70 million mobile users, more than 63 million monthly active users (MAUs) across its digital services such as JazzCash, Tamasha, Simosa, and thousands of enterprise clients from small and medium businesses to the country's largest national and multinational conglomerates, supporting the digitalization of Pakistan's economy.
The delegation also met with Finance Minister Muhammad Aurangzeb; Minister of State for IT &amp; Telecommunications Shaza Fatima Khawaja; Jameel Ahmed, the Governor of the State Bank of Pakistan; Pakistan Telecommunications Authority Chairman Major General (R) Hafeez-Ur-Rehman.

Global

VEON

VEON Group Reaffirms Commitment To Strengthen Pakistan's Digital Infrastructure In Meeting With Prime Minister Shehbaz Sharif

Piper Sandler analyst Anna Andreeva maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Overweight and raises the price target from $18 to $22.

WRBY

Piper Sandler Maintains Overweight on Warby Parker, Raises Price Target to $22

Benchmark analyst Daniel Kurnos maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Buy and raises the price target from $180 to $200.

EXPE

Benchmark Maintains Buy on Expedia Group, Raises Price Target to $200

PBYI

Puma Biotechnology shares are trading higher after the company reported better-than-expected Q3 financial results and raised the lower end of its Q24 revenue guidance.

Piper Sandler analyst Patrick Moley maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Overweight and raises the price target from $30 to $32.

Piper Sandler Maintains Overweight on Marex Group, Raises Price Target to $32

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.14</a>.
The company reported sales of $702.47 million, up 13% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41838696/amneal-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $696.80 million</a>.
Generic net revenue increased by 9% to $427.35 million, driven by the strong performance of new product launches and biosimilars.
Specialty net revenue increased 19% to $115.64 million, driven by promoted products in neurology and endocrinology, including the recent launches of CREXONT&nbsp;and ONGENTYS&nbsp;for Parkinson&#8217;s disease.
AvKARE&#8217;s net revenue increased by 21% to $159.49 million, driven by growth across its distribution and government-label sales channels.
Adjusted EBITDA in the third quarter of 2024 was $158 million, an increase of 2% compared to the third quarter of 2023, reflective of strong revenue performance and higher gross margins, partially offset by a $20 million research and development milestone payment associated with the company&#8217;s exclusive license of Omalizumab during the third quarter of 2024.
&#8220;Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth:
<ol>
<li>We launched CREXONT for the treatment of Parkinson&#8217;s disease.</li>
<li>We announced our collaboration with Metsera, Inc. to leverage Amneal&#8217;s expertise and supply next-generation medicines for obesity and metabolic diseases.</li>
<li>We expanded our deep pipeline by in-licensing a new high-value biosimilar,&#8221; said Chirag and Chintu Patel, Co-CEOs.</li>
</ol>
Guidance: Amneal has reaffirmed its 2024 revenue guidance of $2.7 billion—$2.8 billion and adjusted EPS of $0.57-$0.63, versus the consensus of $2.76 billion and $0.60, respectively.
The company expects 2024 adjusted EBITDA of $610 million—$630 million, operating cash flow&nbsp;of $280 million—$320 million and capital expenditures of $60 million—$70 million.
Price Action: At last check on Friday, AMRX stock down up 4.88% to $8.19 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/24/11/41839609/asia-markets-mixed-europe-crude-oil-gold-and-dollar-cool-off-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia Markets Mixed, Europe, Crude Oil, Gold, And Dollar Cool Off &#8211; Global Markets Today While US Slept</a></li>
</ul>

Comments

Notizie

Ultime notizie per (OTC:HEPZF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO